A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
about
α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?Noradrenergic α₁ receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trialComparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysisClinical ease of using doxazosin in BPH patients with and without hypertension.The α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats.Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction.Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory.Stereoselective binding of doxazosin enantiomers to plasma proteins from rats, dogs and humans in vitro.The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.The effect of alpha-blocker therapy on erectile functions in patients with lower urinary tract symptoms due to benign prostate hyperplasia.Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms.Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.The use of primary and secondary doxazosin XL (8 mg) in the treatment of benign prostate hyperplasia: Is there a new approach in the event of alpha-blocker failure?Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia.A network meta-analysis on the beneficial effect of medical expulsive therapy after extracorporeal shock wave lithotripsy.Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.Controlled-release doxazosin as combination therapy in hypertension: the GATES study.The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
P2860
Q28070342-85B7670E-6635-4410-81E8-E727E3943D23Q28480500-1EC2413F-6AF0-4A19-9550-30D03F0463CAQ28542960-1F56DD05-F849-415A-9AC9-63B970F18796Q30435930-64B902F7-6C38-43D9-867D-504AB704CB16Q30443459-1974DF83-4930-4CBF-900A-74B8D08D9164Q33602395-DB70F876-0CEB-4284-A1E3-0A171E1C9982Q34003918-3F0B3F01-39E1-4A74-B86A-A173AB7813C8Q35545711-C08C9FC1-8DDE-4D1C-A0BA-41A6F56266D8Q35919193-23B5C4C7-CAE7-4312-9C20-ED4DD3CC2B6FQ36116539-9FD44067-27BC-4EB5-91D5-7BCBDFDE1060Q36371582-4A608EFE-53D8-4E99-B862-DD9A78FE6292Q36628673-0937A612-1973-43A3-9A36-0707C1732CE1Q37728436-DB832897-144E-47E8-AFAB-2FB096C151A5Q38364582-E53173FC-1780-49AE-A262-7102A8638681Q38785523-6575A275-485F-44BC-94DD-A129FA8C3D05Q39297278-C744614C-D7C2-4AD1-9268-A3E182F133FBQ39697907-7AA3546A-61B1-45CE-B067-10D5BC4C4CAEQ39820249-10EA859C-E9BC-4548-AFA8-6891DF22E19EQ41469996-8364078C-3417-4BB6-A4CA-BA192E621D9AQ41813716-E6F28818-D34A-46CC-AD26-FEB660C80C3DQ44982532-10360C42-A7A8-4CA2-A693-5770A8D1FA03Q45215945-946480C5-77C4-44FC-9BD9-5C61247C1520Q45260612-E131565D-0F58-4874-AC9E-33D7E746DFCBQ45713774-BBF83BCB-27AB-4D75-8A6D-66451861BFF1Q46730616-4744F418-0D66-4499-B2F2-07E2FE25DAF2Q46786976-2C1618DA-0EE6-4474-A467-A0FD293599A8Q46841503-11AA419E-EFEC-420C-A6C7-CF793FF940DCQ46979869-6E732C8B-AF96-4B04-893B-46EC3E69DF9CQ48130326-2C6D7931-3CAB-4DA8-89AB-DE3BB286C3AA
P2860
A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A combined analysis of double- ...... benign prostatic hyperplasia.
@ast
A combined analysis of double- ...... benign prostatic hyperplasia.
@en
type
label
A combined analysis of double- ...... benign prostatic hyperplasia.
@ast
A combined analysis of double- ...... benign prostatic hyperplasia.
@en
prefLabel
A combined analysis of double- ...... benign prostatic hyperplasia.
@ast
A combined analysis of double- ...... benign prostatic hyperplasia.
@en
P2093
P2860
P1433
P1476
A combined analysis of double- ...... benign prostatic hyperplasia.
@en
P2093
P2860
P304
P356
10.1046/J.1464-410X.2001.02032.X
P577
2001-02-01T00:00:00Z